由于活性成分不足,台湾召回了112万片Thyrocure片;供应保持稳定. Taiwan recalls 1.12 million Thyrocure tablets due to low active ingredient; supply remains stable.

台湾召回了在稳定试验期间发现的112万多片甲状腺素50毫克甲状腺素,这是一种甲状腺机能减退药物,其原因是其活性成分(甲状腺素钠)的含量较低。 Taiwan has recalled over 1.12 million tablets of Thyrocure 50mcg, a hypothyroidism medication, due to low levels of its active ingredient, levothyroxine sodium, discovered during stability testing. 根据制造商Biofrontier Inc.公司的一份自愿报告,收回涉及两批,必须在11月3日前完成。 The recall, prompted by a voluntary report from manufacturer Biofrontier Inc., covers two batches and must be completed by November 3. 官员说,近四年内国内供应充足,预计到2026年初将再增加500 000片片。 Officials say domestic supply is sufficient for nearly four years, with an additional 500,000 tablets expected by early 2026.